Tx for combi of dementia/hyperlipidemia have increased

in the last 2 yrs

Comparative analysis of claims for 2020 and 2022 in the first year of COVID-19

The amount of claims for dementia treatment and hyperlipidemia has increased by more than 50% in the past two years.

 

In the case of dementia treatment, it seems to have increased significantly as the elderly patients' visits to medical institutions decreased in 2020 due to COVID-19.

 

The hyperlipidemia complex is interpreted as the amount of charge has also increased as the post-drugs of statin + edetimive came out all at once.

 

In the '2022 payroll drug claim status' disclosed by the Health Insurance Review and Assessment Service on the 26th, the claim status by ATC code was compared to 2020.

 

The drug with the largest claim in the ACT Code is the treatment for peptic ulcer and gastroesophageal reflux disease, and 1.155.8 trillion won was charged in 2022.

 

Compared to the past 2020, this is an increase of 25.1%.

 

However, the number of listed items decreased by 170 from 1510 to 1340.

 

This formulation is interpreted as a significant increase in claims due to the overlap of the emergence of domestic new drug K-cap, the growth of PPI+ sodium bicarbonate formulation, and the balloon effect after the expulsion of ranitidine.

 

Of course, the decrease in medical use due to COVID-19 in 2020 is also a major increase..

 

In the case of dementia treatment, such a underlying effect was more prominent.

 

Dementia treatment claims increased by a whopping 58.4% when compared to 2020 and 2022, reflecting the decline in visits to medical institutions for the elderly in 2020.

 

In fact, 2019 before COVID-19 had higher dementia treatment claims than in 2020.

 

As visits to medical institutions have gradually normalized since 2021, the demand for dementia treatment has turned to an increasing trend, surpassing 400 billion won last year.

 

During this period, the number of subsympathetic nervous system, which contains choline-alpocerate formulation, increased by 17.4%.

 

This ingredient formulation has been judged as a selection benefit due to salary re-evaluation, but the notice is being delayed due to the suspension of execution, and the marketing of pharmaceutical companies is strengthening, so it seems that the claim is ahead of the dementia treatment.

 

However, the number of listed items has decreased by 109 in two years.

 

The hyperlipidemia complex also increased claims by 56% as 323 items were added in two years.

 

Atojet generics have been pouring out since 2021, and the sales of improved new drugs from domestic companies have grown to 1 trillion won last year.

 

The 16 top ATC code classifications for claims have all grown compared to 2020.

 

However, direct-acting antiviral drugs, which include hepatitis B treatment and hepatitis C treatment, grew only 0.8%, making a contrast.

 

This is interpreted because there are drugs that have a high therapeutic effect, so the number of patients does not increase.

 

In the second year, the number of listed items has also decreased by 199.